EMEA-002575-PIP02-20
Key facts
| Invented name |
Gavreto
|
| Active substance |
pralsetinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0271/2021
|
| PIP number |
EMEA-002575-PIP02-20
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of thyroid cancer
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Roche Registration GmbH
Tel. +41 6168 79411 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|